Two dengue vaccines are currently licensed worldwide, and who should receive one depends on the vaccine, the person’s age, and whether they have had dengue before. The World Health Organization recommends Qdenga (TAK-003), the newer of the two, for children aged 6 to 16 in areas with heavy dengue transmission, given as two doses three months apart. The older vaccine, Dengvaxia (CYD-TDV), is approved in some countries but restricted to people with a confirmed previous dengue infection because of safety concerns in those who have never been exposed. That restriction traces back to a biological quirk of dengue that makes the virus unusually difficult to vaccinate against.
Why Dengue Is Hard to Vaccinate Against
Dengue comes in four distinct serotypes. Catching one gives you lasting immunity to that serotype, but your antibodies against it can actually make a future infection with a different serotype worse. This phenomenon, called antibody-dependent enhancement, occurs when leftover antibodies from a previous infection bind to the new virus without neutralizing it. Instead, the antibody-virus complex gets pulled into immune cells more efficiently, which can lead to higher levels of virus in the blood and more severe disease.
A long-running pediatric study in Nicaragua demonstrated this in humans: the risk of severe dengue was highest within a narrow range of pre-existing antibody levels, while high antibody levels were protective against all symptomatic dengue.
1PubMed Central. Antibody-dependent enhancement of severe dengue disease in humansThis creates a paradox for vaccine developers. A vaccine that generates only a weak or incomplete immune response could leave someone in exactly the vulnerable zone where enhancement kicks in, mimicking a first natural infection and setting the stage for severe disease when the real virus shows up. Any successful dengue vaccine has to thread the needle: produce strong, balanced immunity to all four serotypes without leaving anyone in that dangerous middle ground.
2PubMed Central. The Complexity of Antibody-Dependent Enhancement of Dengue Virus InfectionDengvaxia and the Serostatus Problem
Dengvaxia, made by Sanofi Pasteur, became the world’s first licensed dengue vaccine in 2015. It is a chimeric vaccine built on a yellow fever virus backbone with dengue surface proteins swapped in for all four serotypes.
3PubMed Central. Dengvaxia: the world’s first vaccine for prevention of secondary dengueEarly trial results were encouraging enough for several countries to start mass vaccination campaigns. But follow-up data revealed a serious problem. Among children who had never been infected with dengue before vaccination (called “seronegative”), the vaccine appeared to act like a silent first infection. When these children later encountered wild dengue, they were at elevated risk of severe disease and hospitalization. In the 9-to-11-year-old age group, seronegative vaccinated children were hospitalized for dengue roughly three times more often than would be expected from a natural secondary infection in the general population.
4PubMed Central. Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccineThe fallout was enormous. The Philippines, which had vaccinated over 800,000 schoolchildren, suspended the program. Parents panicked, lawsuits followed, and trust in vaccines more broadly collapsed. Studies of the aftermath found that the Dengvaxia controversy directly fueled measles vaccine hesitancy in parts of the Philippines, contributing to a measles epidemic.
5Journal of Public Health. ‘I was terrified for my child’: understanding the link between the Dengvaxia® controversy and the measles vaccine hesitancy in Pasay City, PhilippinesDengvaxia is still licensed in several countries but now carries a strict requirement: you must have a confirmed previous dengue infection before receiving it. In the United States, the FDA approved it only for children aged 9 to 16 living in endemic areas who have laboratory-confirmed prior dengue. In practice, this means Dengvaxia’s usefulness is limited by the need for pre-vaccination testing.
The Challenge of Testing Before Vaccination
Confirming whether someone has had dengue before is harder than it sounds. The standard approach uses blood tests that detect anti-dengue antibodies, but these tests face two problems. First, antibodies from other closely related viruses, particularly Zika, can cause false positives. Second, rapid diagnostic tests designed for acute dengue diagnosis often perform poorly when repurposed for detecting old infections, where antibody levels are lower.
A field evaluation in Timor-Leste tested two commercially available rapid tests for this purpose. Both were perfectly specific, meaning they did not produce false positives. But their sensitivity was dismal: one detected only about a fifth of truly seropositive individuals, and the other caught fewer than 5%.
6PubMed Central. Field evaluation of rapid diagnostic tests to determine dengue serostatus in Timor-LesteSensitivity improved under laboratory conditions rather than field settings, but a gap remains. Newer rapid tests specifically designed for pre-vaccination screening are in development, including the OnSite Dengue IgG test, which has been evaluated retrospectively against phase 3 trial data.
7PubMed. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic testUntil a convenient, accurate field test is widely available, any vaccination strategy that requires knowing serostatus will be logistically challenging in exactly the low-resource settings where dengue hits hardest.
Qdenga and What the Trial Data Show
Qdenga, developed by Takeda, is a live-attenuated vaccine built on a dengue serotype 2 backbone.
8PubMed. TAK-003: development of a tetravalent dengue vaccineIts phase 3 trial, called TIDES, enrolled over 20,000 children and adolescents across eight countries. The results through about four and a half years of follow-up showed cumulative vaccine efficacy of roughly 61% against lab-confirmed dengue and about 84% against dengue severe enough to require hospitalization.
9The Lancet. Long-term efficacy and safety of a tetravalent dengue vaccine candidate (TAK-003)The protection was not evenly distributed across serotypes, however. Against dengue serotype 2, efficacy was strong regardless of whether participants had prior dengue exposure, reaching about 80% in seropositive and 88% in seronegative individuals. Serotype 1 protection was moderate. Serotype 3 was the weak spot: in people who had never had dengue, the vaccine showed no meaningful efficacy against DENV-3 at all. And for serotype 4, case numbers were too low to draw conclusions.
9The Lancet. Long-term efficacy and safety of a tetravalent dengue vaccine candidate (TAK-003)Longer follow-up extending to roughly seven years has indicated that some degree of protection is maintained across all four serotypes over that period.
10Applied Clinical Trials. Takeda’s Phase III TIDES Trial Confirms Long-Term Efficacy and Safety of Qdenga Dengue VaccineCrucially, Qdenga has not shown the same safety signal that doomed Dengvaxia’s broad rollout. There has been no clear increase in severe dengue among seronegative vaccinees, which is why the WHO has recommended it without requiring a pre-vaccination blood test. That said, the WHO’s advisory group was deliberate about where to deploy it: settings with high dengue burden and high transmission intensity, to maximize public health impact and minimize any theoretical risk in seronegative individuals.
11Takeda. Takeda Announces WHO SAGE Recommendation for Dengue VaccineWho Should Get Vaccinated Now
The WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) recommends Qdenga for children aged 6 to 16, ideally administered one to two years before the age at which dengue hospitalizations peak in a given community. The two-dose schedule, with a three-month gap between shots, is straightforward compared to Dengvaxia’s three doses over a year.
11Takeda. Takeda Announces WHO SAGE Recommendation for Dengue VaccineIn the United States, the situation is more limited. Dengvaxia is the only dengue vaccine with FDA approval, and it is restricted to children 9 to 16 in endemic areas like Puerto Rico, the US Virgin Islands, and American Samoa, with proof of previous dengue infection required. Between 2010 and 2020, dengue outbreaks in these territories produced over 30,000 reported cases, about half of them in children, along with 68 deaths.
12JAMA. Vaccination for Dengue PreventionQdenga is authorized in the European Union, the UK, Brazil, Indonesia, Thailand, Argentina, and several other countries. The European Medicines Agency has approved it for use starting at age four, including for travelers heading to endemic regions.
13Eurosurveillance. Recommendations on use of QDENGA (dengue vaccine) in jurisdictions where it is authorized for travellersWhat About Travelers
If you live in a non-endemic country and plan to visit a region with active dengue, the question of whether to get vaccinated is less clear-cut than it is for residents of endemic areas. Most travelers face relatively short exposure periods, and the vaccine requires two doses three months apart, so the timeline needs planning. Several countries now authorize Qdenga for travelers, but national advisory committees differ on how strongly they recommend it. The Canadian Committee to Advise on Tropical Medicine and Travel, for example, has published guidance acknowledging the authorization of Qdenga for travelers while noting that data on the vaccine’s performance in this specific population remain limited.
The practical consideration: if you are a frequent traveler to dengue-endemic areas, or you plan an extended stay, vaccination may make more sense than for someone taking a single short holiday. Prior dengue exposure matters here too. If you have had dengue before, vaccination is likely to reinforce your existing immunity. If you have never been exposed, the vaccine still appears safe based on available Qdenga data, but the evidence base is thinner for this group, and serotype-specific gaps in protection remain.
Vaccines in the Pipeline
Researchers at the U.S. National Institutes of Health have developed a single-dose live-attenuated vaccine candidate called TV003 (and a variant, TV005). Unlike the two currently licensed vaccines, TV003 may require only one dose. In trials with adults who had no previous flavivirus exposure, a single dose triggered an antibody response to all four dengue serotypes in roughly 74 to 92% of recipients, depending on the formulation.
14PubMed Central. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?A human challenge study provided striking results: all 21 vaccinated individuals who were deliberately exposed to dengue serotype 2 six months later were completely protected. None developed detectable virus in their blood, none developed rash, and none showed drops in white blood cell counts. In the placebo group, 100% developed viremia, 80% got a rash, and 20% developed neutropenia.
15PubMed. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge modelPhase 2 trials in Bangladesh tested TV005 across multiple age groups, including young children. In adults and older children, the immune response was robust. But in the youngest group, children aged 1 to 4, antibody levels to serotypes 1, 3, and 4 waned by three years, with only about a fifth to a quarter remaining seropositive for those serotypes.
16The Lancet Infectious Diseases. Safety and immunogenicity of the live attenuated tetravalent dengue vaccine candidate TV005 in adults, adolescents, children, and young children in BangladeshWhether this waning translates to reduced real-world protection or increased risk remains an open question. Large-scale efficacy trials are the next step, and the timeline for licensure will depend on those results.
Vaccination Plus Mosquito Control
Dengue vaccination does not exist in a vacuum. In most endemic countries, vector control remains the primary line of defense. One increasingly prominent approach involves releasing mosquitoes carrying Wolbachia, a bacterium that reduces the mosquito’s ability to transmit dengue. Mathematical modeling has explored what happens when you combine Wolbachia with vaccination. A modeling study estimated that vaccination alone could reduce dengue cases by about 19%, Wolbachia alone by about 92%, and the two together by about 99%.
17PubMed Central. Modelling the Use of Vaccine and Wolbachia on Dengue Transmission DynamicsA more recent modeling study focused on Brazil found smaller but still meaningful effects: a Wolbachia campaign targeting 300 municipalities would avert roughly 16% of cumulative cases, vaccination about 9%, and both together about 24%.
18medRxiv. Combining vaccination with wMel for dengue control in BrazilThe numbers vary by model assumptions, but the consistent finding is that neither tool alone is likely to eliminate dengue. In Thailand, economic modeling found that once Wolbachia has suppressed transmission substantially, adding vaccination provides only modest additional reductions, because there is simply less virus circulating for the vaccine to protect against.
19PLOS Neglected Tropical Diseases. The economic impact and cost-effectiveness of combined vector-control and dengue vaccination strategies in ThailandThe practical takeaway: vaccination is one layer of protection, and it works best as part of a broader strategy rather than a standalone solution.
Is Dengue Vaccination Cost-Effective
Cost-effectiveness depends heavily on local transmission intensity and the price of the vaccine. In Thailand, modeling of TAK-003 (Qdenga) at an assumed price of $30 per dose found that routine vaccination of six-year-olds with a ten-year catch-up campaign was not just cost-effective but dominant, meaning it both saved money and improved health outcomes compared to no vaccination.
20PLOS Medicine. Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003In the Philippines, earlier modeling of Dengvaxia found it cost-effective from a societal perspective when per-person vaccination costs stayed below roughly $75 to $78.
21PubMed Central. Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the PhilippinesPuerto Rico, with its moderate transmission intensity and higher healthcare costs, presents a different picture. A modeling study there found much higher costs per quality-adjusted life year gained, with the numbers varying substantially depending on transmission levels and the cost of pre-vaccination screening.
22PLoS Neglected Tropical Diseases. Cost-effectiveness of dengue vaccination in Puerto RicoThe common thread: in high-transmission tropical settings, dengue vaccination tends to pay for itself. In moderate-transmission settings, the economics get murkier and depend on vaccine pricing, screening costs, and how much you value preventing severe disease in children.
The Lingering Shadow of Vaccine Hesitancy
Even in countries where dengue vaccination makes strong epidemiological sense, willingness to get vaccinated is not guaranteed. The Dengvaxia debacle left deep scars in the Philippines, where routine childhood immunization rates dropped sharply across the board. Research involving over 2,800 Filipino respondents found that government trust, accessibility of vaccines, and seeing others get vaccinated all played significant roles in shaping willingness to accept a dengue vaccine.
23PubMed. Rebuilding Public Trust: Factors Influencing Dengue Vaccine Uptake in the Aftermath of the Dengvaxia Controversy in the PhilippinesThe lesson extends beyond the Philippines. Any new dengue vaccination program needs transparent communication about what the vaccine can and cannot do, honest acknowledgment of past mistakes, and accessible delivery systems. Qdenga’s profile is genuinely different from Dengvaxia’s, but telling parents “this one is different” after a previous vaccine harmed children is a harder sell than any efficacy data can solve on its own.
Climate Change and the Expanding Map of Dengue
The question of who should get a dengue vaccine is becoming relevant to a much larger slice of the world’s population. Over the past four decades, the climate zones suitable for dengue-transmitting mosquitoes have expanded considerably. The largest increases in suitability have been in equatorial sub-Saharan Africa, Southeast Asia, and northern South America, but significant expansions have also reached into more temperate zones in North America, East Asia, and the Mediterranean.
24Communications Earth & Environment. Population at risk of dengue virus transmission has increased due to coupled climate factors and population growthProjections indicate that much of the southeastern United States could become suitable for dengue transmission by 2050, along with higher-altitude areas in Mexico, northern Argentina, and inland Australia. Coastal cities in eastern China and Japan are also likely to become suitable.
25Nature Microbiology. The current and future global distribution and population at risk of dengueEurope is expected to see some of the largest increases in population at risk, with longer transmission seasons driven primarily by the spread of the Aedes aegypti mosquito.
26PLOS Neglected Tropical Diseases. Global expansion and redistribution of Aedes-borne virus transmission risk with climate changeThese shifts mean that dengue vaccination policy, currently relevant mostly in tropical endemic countries, will increasingly need to be considered by health authorities in places that historically viewed dengue as a traveler’s disease. Southern Europe has already experienced locally acquired dengue cases, and sustained transmission in the southern United States is no longer far-fetched.
Cross-Reactive Immunity From Other Flaviviruses
Dengue does not circulate in isolation. In many parts of the world, people are exposed to Zika virus, yellow fever (including through vaccination), Japanese encephalitis, or other flaviviruses. These viruses are closely enough related that infection with one can shape the immune response to another. Research has shown that the antibody response to any one flavivirus is influenced by a person’s history of prior infections with other members of the same virus family.
27PLOS Neglected Tropical Diseases. Zika virus-specific and orthoflavivirus-cross-reactive IgGs correlate with Zika virus seroneutralization depending on prior dengue virus infectionThis has practical implications for dengue vaccination. Someone who has had Zika might test falsely positive on a dengue serostatus screening test, potentially qualifying them for Dengvaxia when they should not. Conversely, pre-existing flavivirus immunity could alter how effectively a dengue vaccine works, though whether that interaction helps or hinders protection remains an active area of research. As both Zika and dengue continue to co-circulate in tropical regions, untangling these cross-reactive immune responses will be important for optimizing vaccination strategies and avoiding the kind of serostatus misclassification that made Dengvaxia’s rollout so fraught.